Literature DB >> 9754727

Nonsteroidal anti-inflammatory drug-associated upper gastrointestinal lesions in rheumatoid arthritis patients. Relationships to gastric histology, Helicobacter pylori infection, and other risk factors for peptic ulcer.

M Voutilainen1, T Sokka, M Juhola, M Farkkilä, P Hannonen.   

Abstract

BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) are risk factors for peptic ulcer in rheumatoid arthritis (RA) patients, but the contribution of reactive gastritis, concomitant Helicobacter pylori infection, or RA activity to NSAID ulcer pathogenesis is unknown.
METHODS: Ninety-six RA patients taking NSAIDs and dyspeptic sex- and age-matched control patients without NSAID use or an RA diagnosis were enrolled in the study.
RESULTS: Gastric ulcer (GU) was detected in 29 (30%) RA patients and 3 control patients (P < 0.001). Sixteen RA patients and no control patient had an H. pylori-negative GU. The GUs of the RA patients were mainly located in the prepyloric region (28%) and antrum (62%). Nine of the 29 RA patients (31%) with GU had more than 1 ulcer. Erosive gastropathy was detected in 34 (71% H. pylori-negative) RA patients and in 13 (62% H. pylori-negative) control subjects (P < 0.001). Chronic gastritis was observed in 65 RA patients (48% H. pylori-negative) and in 58 control subjects (43% H. pylori-negative) (NS). whereas reactive gastritis was found in only 2 RA patients and in none of the controls. Corticosteroid use was the only independent risk factor for GU: odds ratio was 6.8 (95% confidence interval, 1.3-36.0). The prevalences of duodenal ulcer or esophagitis were not increased in RA patients.
CONCLUSIONS: RA patients using NSAIDs continuously are at a greatly increased risk of developing both H. pylori-negative and -positive GUs, and corticosteroid use is an independent risk factor for ulcer development. Most RA patients have chronic gastritis, whereas reactive gastritis is rarely associated with continuous NSAID use in RA patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9754727     DOI: 10.1080/00365529850171459

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

1.  Therapeutic effect of Streptococcus thermophilus CRL 1190-fermented milk on chronic gastritis.

Authors:  Cecilia Rodríguez; Marta Medici; Fernanda Mozzi; Graciela Font de Valdez
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

Review 2.  Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis.

Authors:  Molly D Magnano; Mark C Genovese
Journal:  Curr Rheumatol Rep       Date:  2005-10       Impact factor: 4.592

Review 3.  Ibuprofen: pharmacology, efficacy and safety.

Authors:  K D Rainsford
Journal:  Inflammopharmacology       Date:  2009-11-21       Impact factor: 4.473

Review 4.  The risk of gastric cancer in patients with duodenal and gastric ulcer: research progresses and clinical implications.

Authors:  Zunwu Zhang
Journal:  J Gastrointest Cancer       Date:  2007

5.  Helicobacter pylori infection and gastroduodenal lesions in patients with systemic lupus erythematosus.

Authors:  Claudia Mendoza-Pinto; Mario García-Carrasco; Socorro Méndez-Martínez; Tania Mogollán-Delfín; Pamela Munguía-Realpozo; Efrén Herrera-Robles; Ivet Etchegaray-Morales; José Luis Gálvez-Romero; Álvaro Montiel-Jarquín; Aurelio López-Colombo
Journal:  Clin Rheumatol       Date:  2019-11-12       Impact factor: 2.980

6.  Candidate SNP Markers of Gender-Biased Autoimmune Complications of Monogenic Diseases Are Predicted by a Significant Change in the Affinity of TATA-Binding Protein for Human Gene Promoters.

Authors:  Mikhail P Ponomarenko; Olga Arkova; Dmitry Rasskazov; Petr Ponomarenko; Ludmila Savinkova; Nikolay Kolchanov
Journal:  Front Immunol       Date:  2016-04-04       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.